Blog
RSS FeedPosted by Michael Wonder on 24 Mar 2021
NICE publishes draft guidance for secukinumab (Cosentyx)
24 March 2021 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 24 Mar 2021
NICE publishes draft guidance for ixekizumab (Taltz)
24 March 2021 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 19 Mar 2021
Ovarian cancer patients to have NICE approved drug combination option on Cancer Drugs Fund
19 March 2021 - A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary ...
Posted by Michael Wonder on 19 Mar 2021
NICE rejects Keytruda for advanced bladder cancer in final guidance
18 March 2021 - The UK’s NICE has issued a second final appraisal document rejecting MSD’s Keytruda for the treatment ...
Posted by Michael Wonder on 18 Mar 2021
UK approval for Daiichi Sankyo’s cholesterol lowering treatments
18 March 2021 - Daiichi Sankyo’s cholesterol-lowering drugs Nilemdo and Nustendi have been approved by the UK National Institute for ...
Posted by Michael Wonder on 10 Mar 2021
NICE publishes updated guidance on the use of pembrolizumab (Keytruda) for patients with untreated, metastatic, non-squamous non-small-cell lung cancer
10 March 2021 - Pembrolizumab was listed in the Cancer Drugs Fund for this indication. ...
Posted by Michael Wonder on 10 Mar 2021
NICE finally publishes final guidance for Aimovig
10 March 2021 - Erenumab has been recommended by NICE for certain patients with migraine. ...
Posted by Michael Wonder on 08 Mar 2021
NICE approves life changing gene therapy for treating spinal muscular atrophy
8 March 2021 - A new and potentially curative one-off gene therapy for babies with the rare genetic disorder spinal muscular ...
Posted by Michael Wonder on 04 Mar 2021
NICE rejects rare blood cancer treatment Poteligeo in final appraisal
4 March 2021 - The UK’s NICE has not recommended Kyowa Kirin’s Poteligeo for the treatment of adults living with ...
Posted by Michael Wonder on 03 Mar 2021
NICE backs NHS use of Lilly’s Olumiant in eczema
3 March 2021 - Eli Lilly’s Olumiant has received a UK NICE recommendation for the treatment of moderate-to-severe atopic dermatitis ...
Posted by Michael Wonder on 26 Feb 2021
Thousands of breast cancer patients to have routine access to NICE-approved drug combination
26 February 2021 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for ...
Posted by Michael Wonder on 25 Feb 2021
NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE
25 February 2021 - NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more ...
Posted by Michael Wonder on 25 Feb 2021
NICE draft guidance recommends sapropterin for children with rare inherited metabolic condition phenylketonuria
25 February 2021 - NICE has today issued draft guidance for public consultation which recommends sapropterin (Kuvan, BioMarin) for treating phenylketonuria ...
Posted by Michael Wonder on 24 Feb 2021
Tecartus recommended by NICE
24 February 2021 - Treatment with autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel) is recommended for use within the Cancer Drugs Fund ...
Posted by Michael Wonder on 17 Feb 2021
Lupin responds to NICE Appraisal Consultation Document on NaMuscla (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders
16 February 2021 - Lupin is disappointed that NICE has published an Appraisal Consultation Document recommending not to approve NaMuscla (mexiletine) ...